Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Non-alcoholic Fatty Liver Disease | 17 | 2024 | 404 | 5.260 |
Why?
|
| Liver Cirrhosis | 11 | 2024 | 901 | 1.480 |
Why?
|
| Elasticity Imaging Techniques | 5 | 2024 | 152 | 1.180 |
Why?
|
| Fatty Liver | 3 | 2025 | 220 | 1.070 |
Why?
|
| Hepatitis C, Chronic | 2 | 2019 | 367 | 0.830 |
Why?
|
| Liver | 6 | 2025 | 1799 | 0.800 |
Why?
|
| Liver Diseases | 3 | 2023 | 381 | 0.790 |
Why?
|
| Stomach Neoplasms | 2 | 2018 | 579 | 0.700 |
Why?
|
| Portal System | 1 | 2021 | 35 | 0.680 |
Why?
|
| Collateral Circulation | 1 | 2021 | 41 | 0.670 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2021 | 43 | 0.650 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 30 | 0.650 |
Why?
|
| Patient Safety | 1 | 2024 | 444 | 0.600 |
Why?
|
| Duty to Warn | 1 | 2019 | 2 | 0.600 |
Why?
|
| Professional Impairment | 1 | 2019 | 3 | 0.600 |
Why?
|
| Alcoholic Intoxication | 1 | 2019 | 13 | 0.590 |
Why?
|
| Confidentiality | 1 | 2019 | 104 | 0.560 |
Why?
|
| Neonatal Abstinence Syndrome | 1 | 2018 | 21 | 0.550 |
Why?
|
| Feeding Behavior | 1 | 2023 | 724 | 0.540 |
Why?
|
| Community Health Services | 1 | 2018 | 92 | 0.520 |
Why?
|
| Global Health | 2 | 2023 | 632 | 0.510 |
Why?
|
| Electric Impedance | 1 | 2017 | 72 | 0.510 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 143 | 0.500 |
Why?
|
| Anthropometry | 1 | 2017 | 190 | 0.500 |
Why?
|
| Patient Compliance | 1 | 2019 | 469 | 0.490 |
Why?
|
| Alcoholism | 1 | 2019 | 246 | 0.490 |
Why?
|
| Acculturation | 1 | 2016 | 61 | 0.490 |
Why?
|
| Severity of Illness Index | 2 | 2025 | 3094 | 0.480 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2016 | 84 | 0.470 |
Why?
|
| Mouth Neoplasms | 1 | 2017 | 98 | 0.470 |
Why?
|
| Arteriolosclerosis | 1 | 2015 | 2 | 0.470 |
Why?
|
| Spleen | 1 | 2016 | 256 | 0.470 |
Why?
|
| Cross-Sectional Studies | 8 | 2023 | 3834 | 0.460 |
Why?
|
| Bile Duct Neoplasms | 1 | 2017 | 131 | 0.460 |
Why?
|
| Mexican Americans | 1 | 2016 | 166 | 0.460 |
Why?
|
| Humans | 37 | 2025 | 131604 | 0.450 |
Why?
|
| Diabetic Angiopathies | 1 | 2015 | 67 | 0.440 |
Why?
|
| Carcinoma | 1 | 2017 | 283 | 0.440 |
Why?
|
| Middle Aged | 16 | 2025 | 28883 | 0.430 |
Why?
|
| Adult | 15 | 2025 | 31702 | 0.430 |
Why?
|
| Adipose Tissue | 1 | 2017 | 495 | 0.420 |
Why?
|
| Thyroid Neoplasms | 1 | 2017 | 248 | 0.420 |
Why?
|
| Internship and Residency | 1 | 2024 | 1215 | 0.410 |
Why?
|
| Risk Factors | 10 | 2024 | 10959 | 0.400 |
Why?
|
| Mass Screening | 1 | 2019 | 825 | 0.400 |
Why?
|
| Exercise | 4 | 2023 | 866 | 0.390 |
Why?
|
| Prevalence | 6 | 2022 | 2694 | 0.390 |
Why?
|
| Obesity | 5 | 2024 | 2390 | 0.380 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 454 | 0.380 |
Why?
|
| Prebiotics | 1 | 2012 | 28 | 0.380 |
Why?
|
| Metagenome | 1 | 2012 | 143 | 0.350 |
Why?
|
| Nutrition Surveys | 5 | 2022 | 327 | 0.340 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 732 | 0.340 |
Why?
|
| Male | 17 | 2024 | 65228 | 0.330 |
Why?
|
| Female | 19 | 2025 | 71145 | 0.330 |
Why?
|
| Life Style | 3 | 2022 | 444 | 0.320 |
Why?
|
| Probiotics | 1 | 2012 | 231 | 0.310 |
Why?
|
| Alcohol Drinking | 2 | 2023 | 348 | 0.290 |
Why?
|
| Weight Loss | 2 | 2023 | 529 | 0.290 |
Why?
|
| Intestines | 1 | 2012 | 592 | 0.280 |
Why?
|
| Hypertension | 2 | 2021 | 1360 | 0.270 |
Why?
|
| Helicobacter pylori | 1 | 2017 | 1358 | 0.270 |
Why?
|
| Helicobacter Infections | 1 | 2017 | 1301 | 0.270 |
Why?
|
| Diet | 3 | 2023 | 1121 | 0.260 |
Why?
|
| United States | 7 | 2022 | 11800 | 0.260 |
Why?
|
| Biomarkers | 4 | 2021 | 3405 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2015 | 866 | 0.260 |
Why?
|
| Aspartate Aminotransferases | 2 | 2016 | 79 | 0.250 |
Why?
|
| Biopsy | 2 | 2020 | 1252 | 0.240 |
Why?
|
| Alanine Transaminase | 2 | 2016 | 156 | 0.240 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2021 | 1413 | 0.240 |
Why?
|
| Prospective Studies | 3 | 2022 | 6494 | 0.240 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2025 | 29 | 0.220 |
Why?
|
| Fibrosis | 3 | 2022 | 414 | 0.220 |
Why?
|
| Reproducibility of Results | 3 | 2025 | 2986 | 0.210 |
Why?
|
| Fast Foods | 1 | 2023 | 23 | 0.200 |
Why?
|
| Aged | 8 | 2025 | 21255 | 0.200 |
Why?
|
| Odds Ratio | 2 | 2016 | 1235 | 0.200 |
Why?
|
| Physicians, Primary Care | 1 | 2024 | 99 | 0.190 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2025 | 338 | 0.190 |
Why?
|
| Glucocorticoids | 1 | 2025 | 350 | 0.190 |
Why?
|
| Cluster Analysis | 1 | 2023 | 418 | 0.190 |
Why?
|
| Disease Management | 2 | 2018 | 564 | 0.180 |
Why?
|
| Young Adult | 4 | 2018 | 10094 | 0.180 |
Why?
|
| Hypertension, Portal | 2 | 2021 | 79 | 0.180 |
Why?
|
| Safety-net Providers | 2 | 2020 | 88 | 0.180 |
Why?
|
| Public Health | 1 | 2023 | 276 | 0.170 |
Why?
|
| Observer Variation | 2 | 2025 | 319 | 0.170 |
Why?
|
| Proof of Concept Study | 1 | 2021 | 39 | 0.170 |
Why?
|
| Actigraphy | 1 | 2021 | 53 | 0.170 |
Why?
|
| Primary Health Care | 2 | 2024 | 787 | 0.160 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 4039 | 0.160 |
Why?
|
| Incidence | 2 | 2018 | 3347 | 0.160 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 546 | 0.150 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 300 | 0.150 |
Why?
|
| Linear Models | 1 | 2021 | 695 | 0.150 |
Why?
|
| Health Behavior | 1 | 2022 | 390 | 0.150 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2019 | 40 | 0.150 |
Why?
|
| Rooming-in Care | 1 | 2018 | 1 | 0.140 |
Why?
|
| Safety | 1 | 2019 | 215 | 0.140 |
Why?
|
| Hepatic Encephalopathy | 1 | 2019 | 82 | 0.140 |
Why?
|
| Risk | 1 | 2020 | 739 | 0.140 |
Why?
|
| Urban Health | 1 | 2018 | 85 | 0.140 |
Why?
|
| Communicable Diseases | 1 | 2020 | 158 | 0.130 |
Why?
|
| Emigration and Immigration | 1 | 2018 | 81 | 0.130 |
Why?
|
| End Stage Liver Disease | 1 | 2020 | 189 | 0.130 |
Why?
|
| Ultrasonography | 2 | 2025 | 974 | 0.130 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2017 | 20 | 0.130 |
Why?
|
| Latin America | 1 | 2017 | 101 | 0.130 |
Why?
|
| Asia | 1 | 2017 | 125 | 0.130 |
Why?
|
| Age Distribution | 1 | 2018 | 429 | 0.130 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 6922 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2024 | 810 | 0.130 |
Why?
|
| Food Supply | 1 | 2017 | 91 | 0.130 |
Why?
|
| Cooperative Behavior | 1 | 2018 | 223 | 0.130 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 221 | 0.130 |
Why?
|
| Work Schedule Tolerance | 1 | 2016 | 41 | 0.130 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2017 | 104 | 0.120 |
Why?
|
| Retrospective Studies | 5 | 2022 | 17666 | 0.120 |
Why?
|
| Self Report | 1 | 2019 | 558 | 0.120 |
Why?
|
| Emigrants and Immigrants | 1 | 2018 | 169 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 463 | 0.110 |
Why?
|
| Dyslipidemias | 1 | 2018 | 247 | 0.110 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2014 | 8 | 0.110 |
Why?
|
| Hydrothorax | 1 | 2014 | 11 | 0.110 |
Why?
|
| Length of Stay | 1 | 2020 | 1399 | 0.100 |
Why?
|
| Antiviral Agents | 1 | 2019 | 812 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 998 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 1405 | 0.100 |
Why?
|
| Disease Progression | 1 | 2019 | 2206 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2024 | 3695 | 0.090 |
Why?
|
| Liver Neoplasms | 1 | 2022 | 1387 | 0.090 |
Why?
|
| Logistic Models | 1 | 2016 | 1831 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2018 | 707 | 0.090 |
Why?
|
| Inflammation | 1 | 2019 | 1492 | 0.090 |
Why?
|
| Registries | 1 | 2018 | 1599 | 0.080 |
Why?
|
| Diarrhea | 1 | 2012 | 311 | 0.080 |
Why?
|
| Age Factors | 1 | 2016 | 2872 | 0.080 |
Why?
|
| Hospitalization | 1 | 2019 | 1939 | 0.080 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2012 | 217 | 0.080 |
Why?
|
| Texas | 1 | 2018 | 3615 | 0.080 |
Why?
|
| Clostridium Infections | 1 | 2012 | 248 | 0.080 |
Why?
|
| Hypertension, Pulmonary | 1 | 2014 | 463 | 0.070 |
Why?
|
| Quality of Life | 1 | 2019 | 2113 | 0.070 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2012 | 328 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 2082 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3454 | 0.070 |
Why?
|
| Time Factors | 1 | 2018 | 6279 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 1139 | 0.070 |
Why?
|
| Prognosis | 1 | 2017 | 4952 | 0.070 |
Why?
|
| Chile | 1 | 2025 | 25 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2018 | 8588 | 0.060 |
Why?
|
| Prednisolone | 1 | 2025 | 69 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1516 | 0.040 |
Why?
|
| Physical Fitness | 1 | 2021 | 89 | 0.040 |
Why?
|
| Menopause | 1 | 2021 | 87 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2021 | 148 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2024 | 706 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 1255 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2020 | 99 | 0.040 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2020 | 152 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2024 | 2297 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2024 | 1695 | 0.030 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 363 | 0.030 |
Why?
|
| Adolescent | 1 | 2015 | 20931 | 0.030 |
Why?
|
| Cross Infection | 1 | 2020 | 338 | 0.030 |
Why?
|
| Hospitals | 1 | 2019 | 445 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2019 | 423 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 1075 | 0.030 |
Why?
|
| Child | 1 | 2015 | 26250 | 0.030 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2014 | 16 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1595 | 0.030 |
Why?
|
| Diuretics | 1 | 2014 | 158 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 5123 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2014 | 1234 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 2567 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 2014 | 1131 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2020 | 12964 | 0.010 |
Why?
|